|
|
???tair.name??? >
???browser.page.title.author???
|
"zhu viola w"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-11-29T06:37:51Z |
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC
|
Zhu, Viola W; YEN-TING LIN; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L; Reungwetwattana, Thanyanan; Lin, Chia-Chi; Soo, Ross A |
| 臺大學術典藏 |
2021-08-22T00:00:09Z |
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
|
Subbiah, Vivek; Hu, Mimi I.; Wirth, Lori J.; Schuler, Martin; Mansfield, Aaron S.; Curigliano, Giuseppe; Brose, Marcia S.; Zhu, Viola W.; Leboulleux, Sophie; Bowles, Daniel W.; Baik, Christina S.; Adkins, Douglas; Keam, Bhumsuk; Matos, Ignacio; Garralda, Elena; Gainor, Justin F.; Lopes, Gilberto; Chia-Chi Lin; Godbert, Yann; Sarker, Debashis; Miller, Stephen G.; Clifford, Corinne; Zhang, Hui; Turner, Christopher D.; Taylor, Matthew H. |
| 臺大學術典藏 |
2020-04-28 |
An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC
|
Soo, Ross A; Chia-Chi Lin; Soo, Ross A;Chia-Chi Lin;Reungwetwattana, Thanyanan;Syn, Nicholas L;Ignatius Ou, Sai-Hong;Tchekmedyian, Nishan;Ock, Chan-Young;Ang, Yvonne L E;To, Hao;Nagasaka, Misako;Loong, Herbert H;Kim, Dong-Wan;YEN-TING LIN;Zhu, Viola W; Zhu, Viola W; YEN-TING LIN; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne L E; Ock, Chan-Young; Tchekmedyian, Nishan; Ignatius Ou, Sai-Hong; Syn, Nicholas L; Reungwetwattana, Thanyanan |
| 臺大學術典藏 |
2020-04-28 |
An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC
|
Soo, Ross A; Chia-Chi Lin; Soo, Ross A;Chia-Chi Lin;Reungwetwattana, Thanyanan;Syn, Nicholas L;Ignatius Ou, Sai-Hong;Tchekmedyian, Nishan;Ock, Chan-Young;Ang, Yvonne L E;To, Hao;Nagasaka, Misako;Loong, Herbert H;Kim, Dong-Wan;YEN-TING LIN;Zhu, Viola W; Zhu, Viola W; YEN-TING LIN; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne L E; Ock, Chan-Young; Tchekmedyian, Nishan; Ignatius Ou, Sai-Hong; Syn, Nicholas L; Reungwetwattana, Thanyanan |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
